Wuhan Bingbing PHARMA was established in 2006 and is the wholly-owned subsidiary of Guojia New Material. It owns a gel preparation standard workshop conforming to GMP requirements, has imported professional medical production equipment, international gel preparation production lines, and perfect inspection equipment. It is a modern enterprise that works on applying and extending biopolymer gel in some fields, including medicines, medical devices, and cosmetics, and integrates with technology research and development, service, production and marketing.
The annual production capacity of existing gel patch for external use (a total of 50 million gel patches) is 20000pcs. The gel patch base is 200 tons, 8631 medical water retention gel materials are 1000 tons. The annual output value exceeds hundreds of millions of Yuan. The company owns supporting advanced production equipment and instruments, green and top-ranking working environment. In addition, the company owns several experts and professors who engage in medicines and applied researches of biopolymer, as well as a batch of scientific and management personnel with abundant experience.
The company advocates the operation philosophy of “human-scientific first” and “quality and service quality”, keeps in close relation with famous colleges in various aspects for long-term. Afterwards, he combined with China University of Geosciences to establish a “gel R &D center”, set up “medicine gel material R&D center” with South-Central University for Nationalities”, so as to combine with development, resource sharing, and abundant scientific ability.
Based on traditional plasters, the company adopts new technology and new materials to develop new-type transdermal delivery products connecting international level and develop modern transdermal delivery industry. The newly-established wholly-owned subsidiary—Wuhan Bingbing PHARMA is specialized in taking charge of commercial cooperation with global superior pharmaceutical enterprises and products and strives for realizing spanning development of pharmacy group as early as possible.